VALANX Biotech

VALANX Biotech is a leading biotechnology company dedicated to the development of superior protein conjugates and Antibody-Drug-Conjugates (ADCs). Located at Plöcking 1, 3400 Klosterneuburg, Lower Austria, VALANX Biotech offers cutting-edge solutions through its GoldenSite™ technology, ensuring a worry-free conjugation process applicable to any payload. With a focus on both CHO and E. coli platforms, VALANX Biotech is positioned to revolutionize the bioconjugation landscape. Another office is located at Rinnböckstrasse 3, 3, Vienna, Austria 1030.

VALANX Biotech specializes in site-specific conjugation, research and development, and novel format conjugates. The company's expertise extends to PEGylation, radioconjugates, and next-generation bioconjugates, providing comprehensive solutions for biopharmaceutical companies seeking to fast-track their development processes. By partnering with VALANX Biotech, clients gain access to unparalleled precision in protein conjugation, optimizing for stability, aggregation, superior efficacy, and an enhanced therapeutic window.

VALANX Biotech's streamlined process ensures efficient development, from initial consultation to data collection and decision-making. The company is committed to staying ahead in the rapidly evolving field of biotechnology, offering innovative solutions that drive the next wave of advancements in protein conjugates and ADCs. The team is ready to support your projects and collaborations. We invite the manager of VALANX Biotech to create a customized and exclusive company showcase and product listing on our platform.